The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before November 17, 2025.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Cytokinetics led investors to believe that it expected FDA approval on its NDA for aficamten in the second half of 2025. The Company failed to inform the market of material risks of its NDA not achieving approval based on its failure to submit a Risk Evaluation and Mitigation Strategy (“REMS”), which could delay the FDA’s processing. The Company revealed on May 6, 2025, that it had multiple pre-NDA meetings with the FDA about safety and mitigation of risk but still chose to submit its NDA without a REMS. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Cytokinetics, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250918417667/en/